Showing results (231-240 of 264) with videos related to
Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded BiopsiesDavid W Scott, Pau Abrisqueta, George W Wright, et al.Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cellsLesley A Mathews Griner, Rajarshi Guha, Paul Shinn, et al.The Journal of Experimental Medicine|September 29, 2023
TLR9 ligand sequestration by chemokine CXCL4 negatively affects central B cell toleranceElif Çakan, Marie Dominique Ah Kioon, Yolanda Garcia-Carmona, et al.Blood|September 29, 2019
Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistryCatalina Amador, Timothy C Greiner, Tayla B Heavican, et al.Blood|August 13, 2017
Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targetsAlyssa Bouska, Chengfeng Bi, Waseem Lone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, et al.Blood|December 16, 2014
Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphomaJaveed Iqbal, Yulei Shen, Xin Huang, et al.Blood|June 19, 2008
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative studyKen H Young, Karen Leroy, Michael B Møller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneNathalie A Johnson, Graham W Slack, Kerry J Savage, et al.Blood|July 28, 2005
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival predictionSilvia Bea, Andreas Zettl, George Wright, et al.Pageof 27